Open Field 66 · Information services
Guides, comparisons, and research summaries for people trying to understand ibogaine and alcohol use disorder without mistaking early evidence for established treatment.
These are informational offerings, not clinical services. They are designed to help readers identify what research can say, where it remains limited, and why safety and regulation belong in the same conversation as possible benefit.
Plain-language guides organize the questions people often bring to ibogaine and alcohol addiction: what ibogaine is, why it is discussed, and why ibogaine therapy benefits should be read with attention to study design, risk, and uncertainty.
Comparison pages separate reported experiences from evidence that can support a conclusion. They include practical context around whether ibogaine treatment works while avoiding claims that a research signal is a promised outcome.
A working glossary explains the language that can obscure an already difficult topic, including the informal labels around ibogaine street names and the distinction between drug terminology, research terminology, and treatment language.
Safety-focused summaries put reports of ibogaine aftereffects beside the broader issue of medical screening, drug interactions, and cardiac risk. The U.S. Food and Drug Administration notes that drug development depends on evidence of safety and effectiveness before approval for marketing.
Research summaries
Research summaries describe what was studied, who was included, what was measured, and what a study cannot establish. Alcohol use disorder is a recognized medical condition, and the National Institute on Alcohol Abuse and Alcoholism’s overview of alcohol use disorder explains why severity, pattern of use, and co-occurring concerns matter when discussing care.
Our coverage also follows adjacent questions without collapsing them into the alcohol-focused evidence. Readers comparing discussions of mood should distinguish ibogaine for depression from the separate topic of ibogaine and depression, because similar language does not make the underlying evidence interchangeable.
For the broader subject, the ibogaine and alcohol addiction research digest brings safety, legal context, and study limitations together in one place. The purpose is orientation, not a recommendation to pursue a substance or a substitute for individualized medical care.
How we frame uncertainty
“Promising questions are not the same thing as established treatment.”
The information here is organized for careful comparison: reported outcomes, gaps in follow-up, safety signals, and the legal landscape. For context about how the resource approaches those limits, see our purpose and editorial principles. Cost-focused searches, including those for affordable ibogaine treatment, can add urgency, but cost does not reduce the need for reliable safety information.
The goal is not to settle personal decisions remotely. It is to make common claims, comparisons, and terminology easier to inspect.
Regulation affects what claims can responsibly be made and how a substance is understood in a given setting. The general background on ibogaine can be a starting point for terminology, but it does not replace review of primary research or professional advice.
People may search for ibogaine treatment in Seattle while trying to make sense of access, law, and safety. Our role is informational: to clarify questions that should be considered, not to direct people to a provider or promise a result.
Evidence before claims
Open Field 66 is an independent resource for people affected by alcohol use disorder, loved ones, and anyone seeking a careful understanding of ibogaine research and safety.
Explore the research overview